Why is the comparison with Medicare for OPZELURA 1.5% CREAM labelled estimated?

Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Opzelura / Ruxolitinib Phosphate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's GM. Joined on brand name.

Why does this page start at 60 g?

NADAC prices this product per GM. The FDA NDC Directory’s package description gives 60 g in one package for this product’s NDC (“1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE”), so the card starts at one package: 60 GM. Change it to match your prescription.

OPZELURA 1.5% CREAM

FDA nonproprietary name: ruxolitinib

For 60 g

Pharmacies pay

$2,040.71 filed

60 × $34.01191 per GM

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$1,977.80 filed

60 × $32.9633 per GM, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

The spread

0.97× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Opzelura” / “Ruxolitinib Phosphate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$2,351.82 estimated

$2,040.71 + $306.11 (15%) + $5.00 fee per fill = $2,351.82

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

OPZELURA 1.5% CREAM is how the CMS NADAC file names this product. The FDA NDC Directory lists it as ruxolitinib, under the trade name “OPZELURA”.

FDA gives its dosage form as cream and its route as topical.

The labeler, the company named on the label, is Incyte Corporation.

FDA lists it under 2 Established Pharmacologic Classes: Janus Kinase Inhibitor and Kinase Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 50881-0007-05.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $2,040.71 for 60 g (60 × $34.01191 per GM, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

50881-0007-05 · Incyte Corporation · $34.01191 per GM · eff. 2026-09-23 filed

What Medicare paid

Medicare Part D paid $1,977.80 for 60 g, at an average of $32.9633 per GM in 2024 (2024-01-01 to 2024-12-31) for “Opzelura” and “Ruxolitinib Phosphate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 50,464 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

What is your cash price for 60 g? Is it lower than what I would pay through my insurance?
How much is in the package I am getting? This page uses 60 g; your package may hold a different amount.
If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.

Questions

Why is the comparison with Medicare for OPZELURA 1.5% CREAM labelled estimated?: Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Opzelura / Ruxolitinib Phosphate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's GM. Joined on brand name.
Why does this page start at 60 g?: NADAC prices this product per GM. The FDA NDC Directory’s package description gives 60 g in one package for this product’s NDC (“1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE”), so the card starts at one package: 60 GM. Change it to match your prescription.

Its pharmacologic classes

Janus Kinase Inhibitor 12 products
Kinase Inhibitor 23 products